Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI is the most prescribed ROS1 TKI in in both first-line and overall new patient starts in 2026 based on IQVIA claims from first five months of the...
Covered in this story
What has happened since
- IQVIA is up 15.5% since this was published, 75 days ago.
- Nuvation Bio Inc Class a is down 23.4% since this was published, 75 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on IQVIA
- Stifel: $266 → $303 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $IQV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on IQVIA →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.